Before 2001, CML was a life-threatening disease, often with a fatal outcome. In 2001, this changed with the arrival of the first tyrosine-kinase inhibitor: imatinib (Glivec ©). Since then, CML has turned into a chronic disease instead of an often fatal one. Patients who are treated with tyrosine-kinase inhibitors (TKIs) according to the treatment guideline and who respond well to the treatment now have almost normal chances of survival.
TKIs are agents that inhibit the protein responsible for the development of CML. After imatinib, several others TKIs were developed. There are currently five types of TKIs in use, all in the form of tablets. The following three agents are used for standard treatment:
- Imatinib (Glivec)
- Nilotinib (Tasigna)
- Dasatinib (Sprycel)
If one or more of these products do not work (sufficiently) or if you experience a lot of side effects, you can switch to:
- Bosutinib (Bosulif)
- Ponatinib (Iclusig)
CML Treatment guideline
The treatment guideline describes the optimal treatment for people with chronic myeloid leukemia. This is based on the available scientific publications (evidence-based). The guideline is leading, but it is always possible to deviate from it if there is a good reason to do so. CMyLife has plotted the guideline in a timeline, enabling you to track how you are responding to the treatment and what the next steps are based on your lab results.